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Abstract
Background:
Digital whole slide imaging may be useful for obtaining second opinions and is used in many countries. However, the
U.S. Food and Drug Administration requires verification studies.
Methods:
Pathologists were randomized to interpret one of four sets of breast biopsy cases during two phases, separated by ≥9
months, using glass slides or digital format (sixty cases per set, one slide per case, n = 240 cases). Accuracy was
assessed by comparing interpretations to a consensus reference standard. Intraobserver reproducibility was assessed

by comparing the agreement of interpretations on the same cases between two phases. Estimated probabilities of
confirmation by a reference panel (i.e., predictive values) were obtained by incorporating data on the population
prevalence of diagnoses.
Results:
Sixty-five percent of responding pathologists were eligible, and 252 consented to randomization; 208 completed
Phase I (115 glass, 93 digital); and 172 completed Phase II (86 glass, 86 digital). Accuracy was slightly higher using
glass compared to digital format and varied by category: invasive carcinoma, 96% versus 93% (P = 0.04); ductal
carcinoma in situ (DCIS), 84% versus 79% (P < 0.01); atypia, 48% versus 43% (P = 0.08); and benign without
atypia, 87% versus 82% (P < 0.01). There was a small decrease in intraobserver agreement when the format changed
compared to when glass slides were used in both phases (P = 0.08). Predictive values for confirmation by a reference
panel using glass versus digital were: invasive carcinoma, 98% and 97% (not significant [NS]); DCIS, 70% and 57%
(P = 0.007); atypia, 38% and 28% (P = 0.002); and benign without atypia, 97% and 96% (NS).
Conclusions:
In this large randomized study, digital format interpretations were similar to glass slide interpretations of benign and
invasive cancer cases. However, cases in the middle of the spectrum, where more inherent variability exists, may be
more problematic in digital format. Future studies evaluating the effect these findings exert on clinical practice and
patient outcomes are required.
Keywords: Breast cancer, diagnostic accuracy, digital whole-slide imaging, intraobserver reproducibility

INTRODUCTION
Cancer diagnoses rely on a pathological interpretation of biopsy tissue using traditional glass slide microscopy. The
process frequently involves obtaining second opinions before initiating treatment. Numerous prior studies have
shown that more than 10% of breast biopsy diagnoses are changed after obtaining a second review.[1,2,3,4,5,6]
Digital whole-slide imaging (WSI) has the potential to transform the diagnostic process by creating high-resolution
digital images of glass slides that are easily transported electronically and viewable on a computer monitor with pan
and zoom features, which emulates screening a glass slide at varied magnification. The digital format has replaced the
microscope in many medical schools, clinical conferences, and medical board tests[7,8,9] and is diffusing into
clinical practices for telemedicine and archiving, including rapid retrieval.[10] Telepathology using digital WSI could
accelerate pathology consultations and aid the field of oncology.
While the digital format is increasingly used internationally in Europe and Canada,[11,12,13,14,15,16,17] it is not
approved by the Food and Drug Administration (FDA) for primary diagnostic interpretation in the U.S.[11] Although
several studies report promising outcomes using digital WSI, often fewer than 12 pathologists participated in these
studies, or participating pathologists were experts in their clinical field, and the spectrum of cases was often limited to
just a few diagnostic categories or prototypical cases.[14,15,16,17,18,19,20,21,22] More robust studies will be
required by the FDA to sufficiently validate digital WSI technology.
The digital format may be particularly useful for breast specimens given the high volume of biopsies[23] and
challenges associated with interpreting breast pathology.[24]
In this prospective randomized study, we evaluate the results of 208 practicing U.S. pathologists randomly assigned
to interpret breast biopsy specimens in either traditional glass slide or digital WSI format. We also evaluate the
potential for improvement with experience using the digital format during their test set interpretation, and we
calculate the predictive value of cases interpreted using digital WSI by estimating the likelihood of diagnostic
confirmation by a reference consensus panel.

METHODS
Institutional review boards
The Institutional Review Boards at Fred Hutchinson Cancer Research Center (#9249), the University of Vermont
(#M13-269), and the University of Washington (#43717) approved all study activities. Pathologists provided
informed consent. All activities were HIPAA compliant.

Test case development
Test set case development and study design are previously described.[24,25,26,27] Briefly, 240 breast biopsy
specimens were randomly selected from pathology registries. Each case included standardized data on the woman's
age at biopsy, breast density, and biopsy type. We oversampled cases with atypia (atypical ductal hyperplasia [ADH]
and ADH in a papilloma) and ductal carcinoma in situ (DCIS), biopsies from women aged 40–49 years, and cases
from women with dense breasts. Nearly half of the 240 cases were from women aged 40–49 years (n = 118); the
remainder were from women aged 50–59 years (n = 67), 60–69 years (n = 29), and >70 years (n = 26). Breast
Imaging-Reporting and Data System breast density categories assessed on the previous mammography included
almost entirely fat (n = 13), scattered fibroglandular densities (n = 105), heterogeneously dense (n = 97), and
extremely dense (n = 25).[28] Cases were from both core needle (n = 138) and excisional (n = 102) biopsies. The 240
cases were randomly assigned to one of four test sets, with stratification to achieve balance for these factors.
Each glass slide was scanned using an iScan Coreo Au® digital slide scanner in 40× high-resolution mode. A
technician and an experienced breast pathologist reviewed each digital image, rescanning as needed to obtain the
highest quality. A custom online digital slide viewer was built using HD View SL, Microsoft's open source Silverlight
gigapixel image viewer. The viewer, like popular online mapping applications and industry-sponsored WSI viewers,
allowed pathologists to pan the image and zoom (up to 40× actual scanned magnification with additional digital
magnification for a final maximum magnification of 60×). Additional tools were available for measuring lesion size
and counting mitotic figures.
Determination of reference standard
Three experienced breast pathologists developed a reference interpretation by consensus agreement for each case in
glass format using standardized diagnostic categories.[24] The case distribution, defined by glass slide reference
categories, was: benign without atypia (30%), atypia (30%), DCIS (30%), and invasive carcinoma (10%). We present
all data in comparison to the glass slide reference diagnoses. Reference panel members independently interpreted all
cases again in digital format approximately 19 months after glass slide interpretation and established a digital format
reference diagnosis.
Pathologist recruitment, selection, and baseline data collection
The study pathologists were recruited from eight U.S. states (AK, ME, MN, NH, NM, OR, VT, and WA), had
completed residency training, had interpreted breast specimens for ≥1 year, and intended to continue interpreting
breast specimens for ≥1 year. Pathologists were invited to participate through E-mail(s), subsequent mail invitations,
and telephone calls. After enrolling, pathologists completed a demographic and practice characteristic survey.
Test case interpretations
Pathologists were randomly assigned to a test set and interpretive format (glass slide vs. digital) for Phase I, stratified
by clinical expertise (defined by self-reported expertise in breast pathology and/or completion of a breast pathology
fellowship). All interpretations were performed by pathologists using their own microscopes and computers. After at
least 9 months, the pathologists were invited to interpret cases in Phase II. The pathologists were again randomly
assigned to interpretive format in Phase II, with stratification based on Phase I format and clinical expertise [Figure 1
and Appendix 1].
The pathologists interpreted the same cases in both phases; however, the cases were randomly ordered for each
participant and also for each phase. Pathologists were not informed that the cases in Phase II were the same exact,
reordered cases they had already interpreted in Phase I. Pathologists used a web-based form to document
interpretations and indicate whether they desired a second opinion for each case.[24,27] Pathologists received up to
20 hours of Category 1 Continuing Medical Education (CME) credits after participating.
Statistical analyses
We calculated case agreement rates for Phase I with the reference diagnoses as a measure of accuracy for glass and
digital format. A priori, we planned to use Phase I data only when comparing accuracy to avoid assumptions about
carryover effects from Phase I to Phase II and because we had sufficient statistical power from Phase I data. Tests for
agreement rates and confidence intervals (CIs) accounted for both within- and between-participant variability by

employing variance estimates of the form (var [ratep] + [avg (ratep) × (1 – avg (ratep))]/nc)/np, where avg (ratep) is
the average rate among pathologists, var (ratep) is the sample variance among pathologists, nc is the number of cases
interpreted by each pathologist, and np is the number of pathologists. Effects of pathologist characteristics (e.g.,
expertise, digital experience) and case characteristics (e.g., patient age, biopsy type) on accuracy were examined.
Results of the 6-point Likert scales for confidence and difficulty ratings were simplified to a binary variable of 1, 2, 3
versus 4, 5, 6.
When rate comparisons involved more than one factor or more than two levels for a single factor, we used logistic
regression models of agreement rates with a robust variance estimator to account for the lack of independence
between interpretations by the same pathologist.
We used logistic regression to examine if the effect on accuracy of glass versus digital format remained after
adjusting for pathologist characteristics. Adjusting for case-level characteristics was unnecessary, as pathologists
interpreted the same cases, eliminating the potential for case-level characteristics to confound the glass versus digital
comparison.
We evaluated whether a learning curve existed as pathologists became more experienced using the digital format
during this study. In this analysis, the average pathologist-level accuracy was estimated separately for each of the six
consecutive subsets of ten cases in a pathologist's sequence of cases. We used logistic regression with an ordered
covariate with values one to six indicating interpretive sequence (i.e., group of ten cases) to determine if there was an
increasing trend.
To assess reproducibility, pathologists’ interpretations in Phase II were compared with their interpretations of the
same cases in Phase I. Agreement rates and CIs were based on logit models utilizing a robust estimator of the
variance to account for correlation of case interpretations from the same pathologist. Differences in reproducibility
(agreement rates) were calculated when using glass slides in both phases, when using digital format in both phases,
and when the format changed between phases (e.g., using glass slides in one phase and digital in the other).
Hypothesis tests were based on Wald tests of logit model coefficients distinguishing between interpretations made on
different combinations of diagnostic formats.
We calculated the probability that an initial biopsy interpretation in clinical practice using the digital format would be
confirmed by the reference diagnosis (i.e., the predictive value). We used previously described techniques[29]
combining the Phase I data with the prevalence of diagnostic outcomes in U.S. women 50–59 years old who received
breast biopsies after screening.[30]

RESULTS
Characteristics of participating pathologists
Of responding pathologists, 252 (65%) were eligible and agreed to participate [Figure 1 and Appendix 1]. Between
participating pathologists and those who declined or whom we were unable to contact, there were no statistically
significant differences in mean pathologist age, sex, or the proportion working in a population of 250,000 or more.
[24] Table 1 shows the characteristics and clinical experience of the 208 pathologists completing Phase I.
Approximately half (48%) reported using the digital format in their professional work, mostly during conferences and
teaching. While most (93%) pathologists reported confidence when interpreting breast pathology, 55% reported that
breast pathology is challenging, and 44% reported that breast pathology makes them more nervous than other
pathology types.
Pathologists’ confidence by interpretive format
Phase I results include 6,900 interpretations in glass slide format and 5,580 in digital format. When comparing glass
slide versus digital format, pathologists reported similar rates of confidence (81.7% vs. 78.6%, P = 0.22) and
percentage of interpretations marked as borderline between two diagnoses (26.1% vs. 24.6%, P = 0.35). However,
glass slide interpretations were less likely than digital interpretations to be rated as challenging cases (30.0% vs.
38.5%, P = 0.003), and pathologists were less likely to desire a second opinion on glass than on digital interpretations
(35.5% vs. 42.5%, P = 0.03).
Accuracy by format

Pathologists’ accuracy within each diagnostic category was 3–5% higher for pathologists interpreting glass slides
compared to those assigned to digital format: benign without atypia (glass: 87%, digital: 82%; P < 0.01); atypia
(glass: 48%, digital: 43%; P = 0.08); DCIS (glass: 84%, digital: 79%; P < 0.01); and invasive carcinoma (glass: 96%,
digital: 93%; P = 0.04) [Table 2 and Figure 2]. Similar trends occurred when compared to the reference standard
established by experts using the digital format, though the differences were slightly smaller, ranging from 2% to 3% [
Appendix 2].
The pathologist and case characteristics associated with accuracy using digital format (and lack thereof) were
consistent with those previously observed in the interpretation of glass format [Appendix 3]. For example,
pathologists reporting higher breast interpretation case volume had higher accuracy in both interpretive formats, and
accuracy was not influenced by patient age or breast biopsy type. Biopsy interpretations from women with dense
breast tissue on prior mammography also had lower accuracy in the digital format compared to low-density breast
tissue, similar to findings in traditional glass.
Reproducibility (intraobserver agreement between Phase I and Phase II)
Pathologists (n = 172) who completed interpretations in both phases on the same cases provided a total of 20,640
individual case assessments. Intraobserver agreement between interpretations of the same case (Phase I vs. Phase II)
by diagnostic category and interpretive format is shown in Figure 3 and Appendix 4. The overall intraobserver
agreement was highest when glass format was used in both phases at 79% (95%CI: 77%–81%). When the
interpretive format changed between phases, the intraobserver agreement was slightly lower at 77% (95%CI: 75%–
78%) but not statistically significantly different from the findings noted when the glass format was used in both
phases (P = 0.08). A statistically significant difference, however, was noted when the glass format was used in both
phases versus when the digital format was used in both phases, where the overall intraobserver agreement was 73%
(95%CI: 71%–76%; P < 0.001). While pathologists’ reproducibility was high for cases of invasive breast carcinoma,
regardless of which format was used in the two phases or whether the format changed (93%–97%), it was low for
cases in the middle categories such as atypia (56%–62%), regardless of interpretive format.
Evaluation for a learning curve among pathologists in the digital format
No learning curve was observed over the sixty cases interpreted digitally in Phase I (P = 0.85). There was also no
difference in the accuracy between Phase II and Phase I among pathologists randomized to the digital format in both
phases (P = 0.90). This was also true for pathologists randomized to the glass slide format in both phases (P = 0.35).
Predictive values of digital format compared with glass slide interpretations
The estimated numbers of cases under- and over-interpreted in the U.S. (i.e., that would be reclassified to a different
diagnostic category by the reference consensus panel review) is shown in Figure 4 by interpretive format and
diagnostic category of the initial interpretation [Appendix 5]. The predictive values for cases initially interpreted as
invasive breast carcinoma are similar regardless of interpretive format. For example, a slide interpreted digitally as
invasive carcinoma was 97.2% (95%CI: 95.6%–98.6%) likely to be confirmed as invasive carcinoma by our expert
reference panel using the original glass slide. This is comparable to the previously reported predictive value when the
initial interpretation was obtained by glass slide of 97.7% (95%CI: 96.5%–98.7%).[29] Similarly, interpretations of
benign without atypia were highly likely to be confirmed by the reference panel regardless of format (95.7% digital
vs. 97.1% glass).
Of note, the estimated predictive values were significantly lower for atypia and DCIS in the digital interpretation
format compared with glass interpretations (Wald test: atypia P = 0.002; DCIS P = 0.007). While these predictive
values were statistically significantly lower for interpretations obtained in the digital format, the predictive values of
these challenging cases as previously reported are also low in the glass format.[29] For example, the predictive values
for an initial atypia interpretation in the U.S. being in agreement with a reference review were 27.8% in the digital
format versus 37.8% glass format, and for DCIS cases, the values were 57.1% digital versus 69.6% glass.
Interpretation time
Pathologists using the digital format spent more time interpreting than pathologists using glass slides, as measured by
total requested CME hours. The percentage of pathologists who reported spending 20 hours participating in the study
(the maximum allowed) was higher among those interpreting in the digital format in both phases versus those

interpreting in the glass format in both phases (76% digital versus 51% glass, respectively; P = 0.01; Wilcoxon ranksum test for difference).

CONCLUSIONS
To date, our study of 240 biopsy cases interpreted by >200 pathologists from across the U.S. is the largest randomized
study comparing traditional glass microscopy and digital WSI. Our study highlights the many challenges we face as
we move into the digital era in the design and analyses of quality assessment studies. In our study, predictive value
estimates were nearly identical regardless of interpretive format at the extremes of the diagnostic spectrum (e.g.,
invasive cancer and benign tissue), suggesting digital WSI could be employed for the primary diagnosis for these
extreme categories. However, the more challenging (and less common) atypia and DCIS diagnostic categories in the
middle of the spectrum have lower reproducibility and accuracy in the digital interpretive format. It should be noted
that reproducibility and accuracy are also lower for atypia and DCIS when using glass slides, but the effect is
amplified using digital WSI. As the field of digital pathology moves forward, attention to inclusion of the full
spectrum of cases in validation studies will be important.
While our study followed the digital imaging validation guidelines recommended by the College of American
Pathologists,[31] our design also exceeded their recommendations in a few notable ways. Our study design included
randomly allocating pathologists to interpretive format, using a random selection process for identifying cases,
including a Phase I glass to Phase II glass reproducibility study arm as a benchmark, and employing a 9-month washout period between phases to reduce recall bias when assessing reproducibility. We also compared pathologists’
accuracy using a carefully defined expert consensus reference standard. Finally, the investigators have no associations
with manufacturers of digital WSI instruments or viewing platforms except that one commercial manufacturer
provided use of a scanner to digitally archive the glass slides.
It is possible that the slightly lower accuracy with digital WSI imaging that we noted can be corrected with
experience. Among pathologists reporting prior experience using digital WSI, we noted a nonsignificant trend for
higher accuracy of digital interpretations than for pathologists who reported no experience with WSI, even after
accounting for the effects of other pathologist-level characteristics. However, participating pathologists had limited
experience with the digital format as it is not currently approved for primary diagnostic use in the U.S. by the FDA. It
may be too early to address whether experience with the digital format results in improved diagnostic accuracy.
In the digital format, pathologists were more likely to deem a case challenging and spent more time interpreting cases
compared to pathologists using glass slides – circumstantial evidence suggesting that experience with the technology
may be an issue. Technological improvements to image acquisition and standardized display systems, coupled with
physician education and experience using digital WSI, may reduce performance gaps between the formats. While no
learning curve was noted in performance during this study, gaining experience requires time, and sixty cases without
an educational intervention may be inadequate. The absence of a learning curve has been noted by others,[22] though
an improvement in accuracy after completing an educational intervention was reported in one study.[32]
Many areas of pathology are challenging and might benefit from digital technology. Pathologists are understandably
concerned about the high level of difficulty of breast pathology[24] and the high risk for medical malpractice when a
cancer diagnosis is a possibility.[33] Pathologists are also likely to desire a second opinion to improve clinical care on
breast cases more often than being required by existing laboratory policies.[34] Digital technology could, therefore,
be an important tool to facilitate second opinions on these challenging cases.
Pathologists interpret differently using traditional glass slide microscopy versus digital WSI format. Behind the
microscope, small finger movements reposition the slide, and eye saccades scan the microscopic field; the remainder
of the head and body are stationary. Digital viewing requires larger hand movements to pan and zoom and greater
head and eye movements to scan all areas of the image. In addition, for pathologists wearing corrective lenses,
particularly bifocals or variable focus lenses, constant corrections are needed to maintain focus. Implementation
studies in Sweden suggest job-specific ergonomics may be improved by incorporating the digital format.[35]
Special considerations in designing quality assessment studies
Technologic improvements in design and image quality are occurring quickly in this field. Going forward, proposed
technical performance parameters and regulation of digital imaging have been outlined by the FDA and discussed by
others.[11,36,37] One potential limitation to this study is that each pathologist completed the histology evaluation

remotely using their own microscope and computer, with no standardization. We do not have information on their
workstation and monitor specifications or internet and bandwidth capabilities. The scanner we used is no longer
commercially available, and scanner technology is rapidly updating. However, the digital whole slide images were
acquired using a 40× objective lens and research staff carefully reviewed the digital scan image of each slide to avoid
errors introduced during digital scanning and to assure quality.
In a randomized study design such as ours, other limiting factors apply equally to both glass and digital formats. For
example, our study included one slide per case, assessment of performance in a testing situation instead of actual
clinical setting, and a higher proportion of benign proliferative, atypia, and DCIS cases than usual clinical practice, as
well as a relatively small number of invasive cancer cases. While these can be considered limitations, these limiting
factors were equally present in the digital and the glass format testing.
Implications
Digital imaging technology has revolutionized medicine and is an important emerging adjunct to traditional light
microscopy that might greatly aid the practice of pathology. We noted that diagnoses of invasive breast carcinoma are
highly reproducible using both glass and digital formats. However, clinical practice includes a broad spectrum of
cases, including those in the middle diagnostic categories, and these cases are often more challenging to diagnose
even in the traditional glass slide format. As noted in this study, the more challenging high-risk and preinvasive
lesions (atypia and DCIS) may have lower predictive value using a digital format compared with a glass slide format.
We encourage future studies evaluating the effect(s) of the digital format on patient outcomes to include the full
spectrum of cases and consider the randomized design features presented in our study.
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Figures and Tables

Figure 1

Flow diagram for pathologist randomization [see Appendix 1 for further details on recruitment and randomization]

Appendix 1a
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Pathologist recruitment and randomization for Phase I

Appendix 1b

Phase II detailed flow diagram for pathologist randomization

Table 1
Characteristics of the 208 participating pathologists shown aggregated and by Phase I random assignment to
traditional glass or digital whole slide imaging interpretation

Open in a separate window

Table 2
Pathologists’ accuracy by interpretive format (Phase I interpretations compared with the consensus panel
reference interpretations)a

Figure 2

Percent of Phase I under- and over-interpretations compared with the consensus reference diagnosis by pathologist interpretive format
(glass slide or digital whole-slide imaging format)

Appendix 2
Rates of over- and under-interpretation and agreement with the reference diagnosis for glass interpretation and
digital interpretation using the digital consensus reference interpretations

Appendix 3
Associations between pathologist and case characteristics and rates of agreement with expert consensus
reference diagnosis when 115 pathologists interpreted breast biopsy cases in glass format, and 93 participants
interpreted in digital format

Open in a separate window

Figure 3

Reproducibility of interpretations: Intraobserver agreement of participants’ interpretations of the same case in Phase I and Phase II by
diagnostic format used by the participant for interpretation in both phases. Data shown by the reference diagnosis of the case (n = 172
pathologists with a total of 20,640 individual case assessments) P-values correspond to comparrisons with intraobserver aggrement of
pathologists who read glass slides in both phases

Appendix 4
Reproducibility of interpretations: Intraobserver agreement between interpretations of the same case in Phase I
and Phase II by diagnostic format used for interpretation. Data are shown by the reference diagnosis of the
case (n=172 pathologists with a total of 20,640 individual case assessments)a

Figure 4

Open in a separate window
Estimated numbers of breast biopsy cases that are under- and over-interpreted in the U.S. Results are shown for the number of cases
that would be reclassified to a more (blue) or less (green) severe diagnostic category by the reference consensus panel diagnosis.
Results pertain to women aged 50–59 years with recent screening mammograms in the U.S. and assume their biopsies were interpreted
by pathologists using either a glass slide or a digitized image (one slide per case and without second opinions)

Appendix 5
Probability that a pathologist's interpretation of a single-slide breast biopsy specimen will be verified by the
reference consensus interpretation in the U.S. population of women aged 50-59 years having screening
mammography
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